AMPK activation ameliorates fine particulate matter-induced hepatic injury

Liying Song1, Shuo Jiang1, Kun Pan1

  • 1Department of Environmental Health, School of Public Health and the Key Laboratory of Public Health Safety, Ministry of Education, Fudan University, Shanghai, China.

Insights

Exposure to fine particulate matter (PM2.5) can harm the liver and disrupt fat metabolism. Activating AMP-activated protein kinase (AMPK) may offer protection against these PM2.5-induced injuries.

Area of Science:

  • Environmental Health
  • Toxicology
  • Metabolic Disease

Background:

  • Epidemiological and animal studies link PM2.5 exposure to respiratory, cardiovascular, and metabolic diseases.
  • Research on PM2.5-induced hepatic injury and its mechanisms remains limited.

Purpose of the Study:

  • To investigate the effects of PM2.5 exposure on hepatic injury and lipid metabolism in brown adipose tissue (BAT).
  • To explore the potential therapeutic role of AMP-activated protein kinase (AMPK) activation in mitigating PM2.5-induced damage.

Main Methods:

  • Male C57BL/6 mice were exposed to filtered air (FA) or concentrated PM2.5 for 12 weeks.
  • Mice received intraperitoneal injections of saline or an AMPK activator (AICAR) during the final week.
  • Liver and BAT tissues were analyzed for gene and protein expression, and histopathological changes were assessed.

Main Results:

  • PM2.5 exposure induced liver steatosis, inflammation, and hepatocyte ballooning, along with BAT swelling.
  • PM2.5-exposed mice showed increased IL-6, TNF-α, NF-κB, and JNK, and decreased AMPK, GLUT4, and UCP-1.
  • AICAR treatment upregulated hepatic GLUT4 expression in PM2.5-exposed mice but did not significantly alter histopathology.

Conclusions:

  • Ambient PM2.5 exposure may cause hepatic injury and disrupt lipid metabolism in BAT.
  • AMPK activation shows potential in ameliorating PM2.5-induced harmful effects, suggesting it as a therapeutic target.

Related Concept Videos

cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
8.0K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
123
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
139